                                SEQUENCE LISTING

<110> Palath, Varghese
      Bebbington, Christopher R.
      KaloBios Pharmnaceuticals, Inc.

<120> EphA3 Antibodies for the Treatment of
  Multiple Myeloma

<130> 87142-803093

<140> WO PCT/US11/30998   
<141> 2011-04-01  

<150> US 61/320,230       
<151> 2010-04-01  

<160> 61

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 118
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H)

<400> 1
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Thr
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
            20                  25                  30          
Trp Met Asn Trp Val Arg Gln Ala Ser Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Asp Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Gly Val Tyr Glu Asp Phe Asp Ser Trp Gly Gln Gly Thr
            100                 105                 110         
Thr Val Thr Val Ser Ser
        115             


<210> 2
<211> 118
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H)

<400> 2
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
            20                  25                  30          
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Asp Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Gly Tyr Tyr Glu Glu Phe Asp Ser Trp Gly Gln Gly Thr
            100                 105                 110         
Thr Val Thr Val Ser Ser
        115             


<210> 3
<211> 118
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H)

<400> 3
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Thr
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
            20                  25                  30          
Trp Met Asn Trp Val Arg Gln Ala Ser Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Asp Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Gly Tyr Tyr Glu Glu Phe Asp Ser Trp Gly Gln Gly Thr
            100                 105                 110         
Thr Val Thr Val Ser Ser
        115             


<210> 4
<211> 118
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H)

<400> 4
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Leu Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Gly Tyr
            20                  25                  30          
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Asp Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Gly Tyr Tyr Glu Glu Phe Asp Ser Trp Gly Gln Gly Thr
            100                 105                 110         
Thr Val Thr Val Ser Ser
        115             


<210> 5
<211> 118
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H)

<400> 5
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
            20                  25                  30          
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Asp Glu Lys Phe
    50                  55                  60                  
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Gly Tyr Tyr Glu Asp Phe Asp Ser Trp Gly Gln Gly Thr
            100                 105                 110         
Thr Val Thr Val Ser Ser
        115             


<210> 6
<211> 118
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H)

<400> 6
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1               5                  10                  15      
Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Thr Tyr
            20                  25                  30          
Trp Ile Ser Trp Val Arg Gln Met Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe
    50                  55                  60                  
Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Gly Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Gly Tyr Tyr Glu Asp Phe Asp Ser Trp Gly Gln Gly Thr
            100                 105                 110         
Thr Val Thr Val Ser Ser
        115             


<210> 7
<211> 118
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H)

<400> 7
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1               5                  10                  15      
Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Thr Tyr
            20                  25                  30          
Trp Ile Ser Trp Val Arg Gln Met Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Ala Gln Glu Phe
    50                  55                  60                  
Arg Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Val Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Gly Tyr Tyr Glu Asp Phe Asp Ser Trp Gly Gln Gly Thr
            100                 105                 110         
Thr Val Thr Val Ser Ser
        115             


<210> 8
<211> 118
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H)

<400> 8
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1               5                  10                  15      
Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Thr Tyr
            20                  25                  30          
Trp Ile Ser Trp Val Arg Gln Met Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe
    50                  55                  60                  
Leu Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Tyr Asp Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Gly Tyr Tyr Glu Asp Phe Asp Ser Trp Gly Gln Gly Thr
            100                 105                 110         
Thr Val Thr Val Ser Ser
        115             


<210> 9
<211> 118
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H)

<400> 9
Glu Val Lys Leu Glu Glu Ser Gly Ala Glu Leu Val Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Asn Phe Thr Ser Tyr
            20                  25                  30          
Trp Ile Asn Trp Val Arg Leu Arg Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Asp Glu Lys Phe
    50                  55                  60                  
Lys Arg Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80  
Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Gly Tyr Tyr Glu Asp Phe Asp Val Trp Gly Gln Gly Thr
            100                 105                 110         
Thr Val Thr Val Ser Ser
        115             


<210> 10
<211> 118
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H)

<400> 10
Glu Val Lys Leu Glu Glu Ser Gly Ala Glu Leu Val Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Asn Phe Thr Ser Tyr
            20                  25                  30          
Trp Ile Asn Trp Val Arg Leu Arg Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Asp Glu Lys Phe
    50                  55                  60                  
Lys Arg Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80  
Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Ser Gly Tyr Tyr Glu Asp Phe Asp Ile Trp Gly Gln Gly Thr
            100                 105                 110         
Met Val Thr Val Ser Ser
        115             


<210> 11
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L)

<400> 11
Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ile Ser Tyr
            20                  25                  30          
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Arg Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Asn Tyr Pro Tyr
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 12
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L)

<400> 12
Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ile Ser Tyr
            20                  25                  30          
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Arg Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ser Asn Tyr Pro Tyr
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 13
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L)

<400> 13
Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ile Ser Tyr
            20                  25                  30          
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Arg Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Gly Gln Tyr Ala Asn Tyr Pro Tyr
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 14
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L)

<400> 14
Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ile Ser Tyr
            20                  25                  30          
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Arg Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Asn Tyr Pro Tyr
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 15
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L)

<400> 15
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ile Ser Tyr
            20                  25                  30          
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Arg Leu Ile
        35                  40                  45              
Tyr Gly Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Asn Tyr Pro Tyr
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 16
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L)

<400> 16
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Thr Tyr
            20                  25                  30          
Leu Asn Trp Ile Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Asn Tyr Pro Tyr
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 17
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L)

<400> 17
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Thr Tyr
            20                  25                  30          
Leu Asn Trp Ile Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Arg Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Asn Tyr Pro Tyr
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 18
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L)

<400> 18
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
            20                  25                  30          
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Arg Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Asn Tyr Pro Tyr
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 19
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L)

<400> 19
Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ile Ser Tyr
            20                  25                  30          
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Arg Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Gln Tyr Ala Asn Tyr Pro Tyr
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 20
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L)

<400> 20
Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ile Ser Tyr
            20                  25                  30          
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Arg Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Ala Lys Tyr Pro Tyr
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 21
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L)

<400> 21
Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ile Ser Tyr
            20                  25                  30          
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Arg Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gly Tyr Ala Asn Tyr Pro Tyr
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 22
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L)

<400> 22
Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ile Ser Tyr
            20                  25                  30          
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Arg Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Val Arg Tyr Ala Asn Tyr Pro Tyr
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 23
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L)

<400> 23
Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
 1               5                  10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ile Ser Tyr
            20                  25                  30          
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Arg Leu Ile
        35                  40                  45              
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Val Gln Tyr Leu Asn Tyr Pro Tyr
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105         


<210> 24
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR3

<220> 
<221> VARIANT        
<222> (1)...(1)
<223> Xaa = Ser or Gly

<220> 
<221> VARIANT        
<222> (3)...(3)
<223> Xaa = Tyr or Val

<220> 
<221> VARIANT        
<222> (6)...(6)
<223> Xaa = Glu or Asp

<220> 
<221> VARIANT        
<222> (9)...(9)
<223> Xaa = Ser, Val or Ile

<400> 24
Xaa Gly Xaa Tyr Glu Xaa Phe Asp Xaa
 1               5                  


<210> 25
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR3

<400> 25
Gly Gly Tyr Tyr Glu Asp Phe Asp Ser
 1               5                  


<210> 26
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR3

<400> 26
Ser Gly Tyr Tyr Glu Glu Phe Asp Ser
 1               5                  


<210> 27
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR3

<400> 27
Ser Gly Val Tyr Glu Asp Phe Asp Ser
 1               5                  


<210> 28
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR3

<400> 28
Ser Gly Tyr Tyr Glu Asp Phe Asp Val
 1               5                  


<210> 29
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR3

<400> 29
Ser Gly Tyr Tyr Glu Asp Phe Asp Ile
 1               5                  


<210> 30
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain FR4

<400> 30
Trp Gly Gln Gly Thr Thr Val Thr Val Ser
 1               5                  10  


<210> 31
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR1, anti-EphA3 antibody FA225-C10 CDRH1

<400> 31
Gly Tyr Trp Met Asn
 1               5  


<210> 32
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR1, anti-EphA3 antibody FA3AM-H12A and K3D
      CDRH1

<400> 32
Thr Tyr Trp Ile Ser
 1               5  


<210> 33
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR1, anti-EphA3 antibody IIIA4 CDRH1

<400> 33
Ser Tyr Trp Ile Asn
 1               5  


<210> 34
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR2, anti-EphA3 antibody FA3AM-H12A and
      FA225-C10 CDRH2

<400> 34
Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Asp Glu Lys Phe Gln
 1               5                  10                  15      
Gly
    

<210> 35
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR2

<400> 35
Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln
 1               5                  10                  15      
Gly
    

<210> 36
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR2, anti-EphA3 antibody K3D CDRH2

<400> 36
Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Ala Gln Glu Phe Arg
 1               5                  10                  15      
Gly
    

<210> 37
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR2

<400> 37
Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe Leu
 1               5                  10                  15      
Gly
    


<210> 38
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR2

<400> 38
Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Asp Glu Lys Phe Glu
 1               5                  10                  15      
Gly
    

<210> 39
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR2, anti-EphA3 antibody IIIA4 CDRH2

<400> 39
Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Asp Glu Lys Phe Lys
 1               5                  10                  15      
Arg
    

<210> 40
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR2

<220> 
<221> VARIANT        
<222> (14)...(14)
<223> Xaa = Lys or Glu

<220> 
<221> VARIANT        
<222> (16)...(16)
<223> Xaa = Gln, Arg or Leu

<400> 40
Asp Ile Tyr Pro Gly Ser Gly Asn Thr Asn Tyr Ala Gln Xaa Phe Xaa
 1               5                  10                  15      
Gly
    

<210> 41
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR3 binding specificity determinant (BSD)

<220> 
<221> VARIANT        
<222> (1)...(1)
<223> Xaa = Gly, Val or Ala

<220> 
<221> VARIANT        
<222> (2)...(2)
<223> Xaa = Gln, Arg or Gly

<220> 
<221> VARIANT        
<222> (4)...(4)
<223> Xaa = Ala, Ser or Leu

<220> 
<221> VARIANT        
<222> (5)...(5)
<223> Xaa = Asn or Lys

<400> 41
Xaa Xaa Tyr Xaa Xaa Tyr Pro Tyr Thr
 1               5                  


<210> 42
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR3, anti-EphA3 antibody FA225-C10 CDRL3

<400> 42
Gly Gln Tyr Ala Asn Tyr Pro Tyr Thr
 1               5                  


<210> 43
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR3

<400> 43
Val Gln Tyr Ala Lys Tyr Pro Tyr Thr
 1               5                  


<210> 44
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR3

<400> 44
Ala Gln Tyr Ala Asn Tyr Pro Tyr Thr
 1               5                  


<210> 45
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR3

<400> 45
Val Gln Tyr Ser Asn Tyr Pro Tyr Thr
 1               5                  


<210> 46
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR3, anti-EphA3 antibody IIIA4 and
      FA3AM-H12A CDRL3

<400> 46
Val Gln Tyr Ala Asn Tyr Pro Tyr Thr
 1               5                  


<210> 47
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR3

<400> 47
Val Gly Tyr Ala Asn Tyr Pro Tyr Thr
 1               5                  


<210> 48
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR3

<400> 48
Val Arg Tyr Ala Asn Tyr Pro Tyr Thr
 1               5                  


<210> 49
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR3, anti-EphA3 antibody FA225-C10 CDRL3

<400> 49
Val Gln Tyr Leu Asn Tyr Pro Tyr Thr
 1               5                  


<210> 50
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic human germ-line Jkappa2 J segment,
      anti-EphA3 antibody FR4

<400> 50
Phe Gly Gln Gly Lys Leu Glu Ile Lys
 1               5                  


<210> 51
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR1, anti-EphA3 antibody FA3AM-H12A, K3D
      and FA225-C10 CDRL1

<400> 51
Arg Ala Ser Gln Gly Ile Ile Ser Tyr Leu Ala
 1               5                  10      


<210> 52
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR1

<400> 52
Gln Ala Ser Gln Asp Ile Ser Thr Tyr Leu Asn
 1               5                  10      


<210> 53
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR1, anti-EphA3 antibody IIIA4 CDRL1

<400> 53
Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Gly
 1               5                  10      


<210> 54
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR1

<400> 54
Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ala
 1               5                  10      


<210> 55
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR2, anti-EphA3 antibody FA3AM-H12A, K3D
      and FA225-C10 CDRL2

<400> 55
Ala Ala Ser Ser Leu Gln Ser
 1               5          


<210> 56
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR2

<400> 56
Gly Ala Ser Ser Leu Gln Ser
 1               5          


<210> 57
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR2

<400> 57
Ala Ala Ser Ser Leu Gln Arg
 1               5          


<210> 58
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody light chain V-region
      (V-L) CDR2, anti-EphA3 antibody IIIA4 CDRL2

<400> 58
Ala Ala Ser Thr Leu Asp Ser
 1               5          


<210> 59
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody heavy chain V-region
      (V-H) CDR3

<220> 
<221> VARIANT        
<222> (6)...(6)
<223> Xaa = Glu or Asp

<400> 59
Ser Gly Tyr Tyr Glu Xaa Phe Asp Ser
 1               5                  


<210> 60
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody IIIA4 heavy chain
      V-region (V-H) CDR3 (CDRH3)

<400> 60
Ser Gly Tyr Tyr Glu Asp Phe Asp Ser
 1               5                  


<210> 61
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-EphA3 antibody K3D light chain
      V-region (V-L) CDR3 (CDRL3)

<400> 61
Val Gln Tyr Met Asn Tyr Pro Tyr Thr
 1               5                  

